Medesis Pharma S.A. (ALMDP.PA)
EUR 0.35
(0.0%)
EUR 0.35
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 1.56 Million EUR | 50.66% |
| 2022 | 1.03 Million EUR | -0.57% |
| 2021 | 1.04 Million EUR | 112.84% |
| 2020 | 490.7 Thousand EUR | -24.62% |
| 2019 | 651 Thousand EUR | -23.32% |
| 2018 | 849 Thousand EUR | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 Q4 | 413.88 Thousand EUR | 0.0% |
| 2023 Q2 | 368.4 Thousand EUR | -1.18% |
| 2023 Q1 | 372.79 Thousand EUR | 32.75% |
| 2023 Q3 | 413.88 Thousand EUR | 12.34% |
| 2023 FY | 1.56 Million EUR | 50.66% |
| 2022 Q1 | 306.35 Thousand EUR | 14.43% |
| 2022 Q4 | 280.82 Thousand EUR | 0.0% |
| 2022 Q3 | 280.82 Thousand EUR | -8.33% |
| 2022 Q2 | 306.35 Thousand EUR | 0.0% |
| 2022 FY | 1.03 Million EUR | -0.57% |
| 2021 FY | 1.04 Million EUR | 112.84% |
| 2021 Q4 | 267.71 Thousand EUR | 0.0% |
| 2021 Q3 | 267.71 Thousand EUR | 5.57% |
| 2021 Q2 | 253.58 Thousand EUR | 0.0% |
| 2021 Q1 | 253.58 Thousand EUR | 101.1% |
| 2020 FY | 490.7 Thousand EUR | -24.62% |
| 2020 Q4 | 126.09 Thousand EUR | 0.0% |
| 2020 Q3 | 126.09 Thousand EUR | 38.16% |
| 2020 Q1 | 91.26 Thousand EUR | 0.0% |
| 2020 Q2 | 91.26 Thousand EUR | 0.0% |
| 2019 FY | 651 Thousand EUR | -23.32% |
| 2018 FY | 849 Thousand EUR | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| ABIONYX Pharma SA | 4.17 Million EUR | 62.543% |
| ABIVAX Société Anonyme | 127.37 Million EUR | 98.772% |
| Adocia SA | 15.62 Million EUR | 89.989% |
| Aelis Farma SA | 18.81 Million EUR | 91.686% |
| Biophytis S.A. | 14.33 Million EUR | 89.084% |
| Advicenne S.A. | 8.21 Million EUR | 80.955% |
| genOway Société anonyme | 16.73 Million EUR | 90.653% |
| IntegraGen SA | 5.35 Million EUR | 70.769% |
| Neovacs S.A. | 10.34 Million EUR | 84.874% |
| NFL Biosciences SA | 4.37 Million EUR | 64.233% |
| Plant Advanced Technologies SA | 2.76 Million EUR | 43.412% |
| Quantum Genomics Société Anonyme | 1.71 Million EUR | 8.929% |
| Sensorion SA | 27.05 Million EUR | 94.217% |
| Theranexus Société Anonyme | 3 Million EUR | 47.934% |
| TME Pharma N.V. | 5.49 Million EUR | 71.538% |
| Valbiotis SA | 9.86 Million EUR | 84.147% |
| TheraVet SA | 1.64 Million EUR | 4.85% |
| Valerio Therapeutics Société anonyme | 20.32 Million EUR | 92.3% |
| argenx SE | 1.34 Billion EUR | 99.883% |
| BioSenic S.A. | 7.58 Million EUR | 79.367% |
| Celyad Oncology SA | 8.49 Million EUR | 81.572% |
| DBV Technologies S.A. | 89.4 Million EUR | 98.25% |
| Galapagos NV | 327.98 Million EUR | 99.523% |
| Genfit S.A. | 54.8 Million EUR | 97.145% |
| GeNeuro SA | 14.35 Million EUR | 89.103% |
| Hyloris Pharmaceuticals SA | 17.98 Million EUR | 91.302% |
| Innate Pharma S.A. | 64.57 Million EUR | 97.577% |
| Inventiva S.A. | 120.18 Million EUR | 98.698% |
| MaaT Pharma SA | 21.59 Million EUR | 92.756% |
| MedinCell S.A. | 32.92 Million EUR | 95.248% |
| Nanobiotix S.A. | 58.92 Million EUR | 97.345% |
| Onward Medical N.V. | 20.64 Million EUR | 92.422% |
| Oryzon Genomics S.A. | 18.49 Million EUR | 91.542% |
| OSE Immunotherapeutics SA | 23.58 Million EUR | 93.367% |
| Oxurion NV | 12.21 Million EUR | 87.19% |
| Pharming Group N.V. | 204.24 Million EUR | 99.234% |
| Poxel S.A. | 28.76 Million EUR | 94.561% |
| GenSight Biologics S.A. | 32.66 Million EUR | 95.21% |
| Transgene SA | 31.23 Million EUR | 94.99% |
| Financière de Tubize SA | 114.38 Thousand EUR | -1267.764% |
| UCB SA | 2.94 Billion EUR | 99.947% |
| Valneva SE | 134.92 Million EUR | 98.84% |
| Vivoryon Therapeutics N.V. | 24.69 Million EUR | 93.664% |